Should I Buy ENTX? ENTX 2026 Analysis

Should You Buy Entera Bio Ltd (ENTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.460

1 Day change

-0.68%

52 Week Range

3.220

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner long-term investor who is impatient. ENTX is in a clear downtrend (bearish moving averages, price below key pivot), has no current proprietary buy signals, and fundamentals show no revenue with ongoing losses—making it an execution- and financing-dependent biotech setup. With $50k–$100k to deploy, this is better treated as a speculative position rather than a core long-term buy, so the recommendation is to avoid/new-buy and effectively “sell”/stay out at current levels.

Technical Analysis

Price/Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (downtrend). The stock is trading below the pivot (1.607) and is sitting right on/just under S1 support (~1.473) in post-market at 1.47; next support is S2 (~1.391). Momentum: RSI_6 at 31.35 suggests near-oversold conditions (weakness may be tiring, but not a confirmed reversal). MACD histogram is slightly positive (0.0126) but positively contracting, indicating any bounce momentum is fading rather than strengthening. Levels: To improve the technical picture, it would need to reclaim the pivot (~1.607) and then resistance at R1 (~1.741). Near-term pattern stats provided imply modest upside odds over a week/month, but the prevailing trend remains down.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is skewed heavily toward calls based on open interest (calls OI 932 vs puts OI 8; put/call OI ratio 0.01). However, trading activity is effectively absent today (0 volume), so current-day sentiment is not confirmed by flow. Implied volatility is very high (30D IV ~173%), but IV percentile is very low (~2.8) and below recent 5–10 day averages, suggesting IV has come down sharply from extremely elevated recent levels—often seen after catalysts or after fear subsides, not necessarily signaling a bullish trend by itself.

Technical Summary

Sell

Buy

Positive Catalysts

Regulatory/program progress: planned FDA submission of the final Phase 3 protocol for EB613 in Q1
Pipeline milestone: Phase 1 bridging study for Next-Gen EB613 with results expected by end of Q1
Program acceleration: hypoparathyroidism program acceleration planned for 2026 based on promising preclinical data.
Potential partnering: strategic partnership discussions could improve funding/commercialization prospects.
Positioning: insiders/hedge funds show neutral activity (no recent negative trend from these groups in provided data).

Neutral/Negative Catalysts

Price action/market behavior: downtrend and a sharp regular-session drop (-5.16%) into key support increases the risk of a breakdown toward S2 (~1.391).
Biotech event risk: value depends on FDA alignment and clinical outcomes (Q1 2026 timeline), which is not near-term for an impatient buyer.
Financing/dilution risk: revenue is currently zero, so continued operations typically rely on cash reserves/raises (not provided here, but implied by loss-making profile).
Options data lacks confirming volume: call-heavy open interest is not backed by active buying today (0 volume).
No proprietary buy signals: Intellectia signals are absent, reducing confidence in a timely entry for someone unwilling to wait.

Financial Performance

Latest quarter: 2025/Q3. Revenue fell to 0 (down 100% YoY), reinforcing a pre-/non-revenue biotech profile. Net income improved slightly to -$3.2M (loss narrowed ~5.93% YoY), but EPS declined to -0.07 (down 12.5% YoY), indicating per-share losses worsened despite the modest improvement in net loss. Overall: still loss-making with no revenue—long-term outcome depends on clinical/regulatory success and funding capacity rather than current operating growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target data was provided, so recent changes and a clear Wall Street consensus trend cannot be quantified here. Qualitative pro view (typical for this setup): pipeline progress, approaching regulatory interactions, and partnering potential. Qualitative con view: non-revenue status, ongoing losses, dilution/financing risk, and binary trial/regulatory outcomes. Politicians/congress: no recent congress trading data available; no influential-figure transactions were provided.

1 Analyst Rating

Wall Street analysts forecast ENTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTX is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.470

Low

Averages

High

Current: 1.470

Low

Averages

High

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

AI Analysis

2025-03-18

Reason